CN103610795B - A kind of preparation method of eucommia bark depressor oral formulations - Google Patents
A kind of preparation method of eucommia bark depressor oral formulations Download PDFInfo
- Publication number
- CN103610795B CN103610795B CN201310657766.2A CN201310657766A CN103610795B CN 103610795 B CN103610795 B CN 103610795B CN 201310657766 A CN201310657766 A CN 201310657766A CN 103610795 B CN103610795 B CN 103610795B
- Authority
- CN
- China
- Prior art keywords
- fluid extract
- eucommia bark
- oral formulations
- preparation
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000208688 Eucommia Species 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 238000009472 formulation Methods 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000012530 fluid Substances 0.000 claims abstract description 61
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 239000002671 adjuvant Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 238000001914 filtration Methods 0.000 claims description 18
- 239000006228 supernatant Substances 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 241000345998 Calamus manan Species 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000012467 final product Substances 0.000 claims description 8
- 235000012950 rattan cane Nutrition 0.000 claims description 8
- 238000002137 ultrasound extraction Methods 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 238000009495 sugar coating Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 27
- 239000003814 drug Substances 0.000 abstract description 13
- 239000000470 constituent Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 14
- 230000036772 blood pressure Effects 0.000 description 11
- 206010020772 Hypertension Diseases 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- ZJSJQWDXAYNLNS-UHFFFAOYSA-N (+) pinoresinol-4,4'-di-O-beta-D-glucopyranoside Natural products COC1=CC(C2C3C(C(OC3)C=3C=C(OC)C(OC4C(C(O)C(O)C(CO)O4)O)=CC=3)CO2)=CC=C1OC1OC(CO)C(O)C(O)C1O ZJSJQWDXAYNLNS-UHFFFAOYSA-N 0.000 description 4
- ZJSJQWDXAYNLNS-FUPWJLLWSA-N (2s,3r,4s,5s,6r)-2-[4-[(3s,3ar,6s,6ar)-6-[3-methoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2-methoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical group COC1=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)CO2)=CC=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZJSJQWDXAYNLNS-FUPWJLLWSA-N 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- IQSFEAHJUMVILC-UHFFFAOYSA-N Isorhynchophyllic acid Natural products CCC1CN2CCC3(C2CC1C(=COC)C(=O)O)C(=O)Nc4ccccc34 IQSFEAHJUMVILC-UHFFFAOYSA-N 0.000 description 4
- DAXYUDFNWXHGBE-VKCGGMIFSA-N Isorhynchophylline Chemical compound O=C1NC2=CC=CC=C2[C@]11CCN2C[C@H](CC)[C@@H](\C(=C/OC)C(=O)OC)C[C@H]21 DAXYUDFNWXHGBE-VKCGGMIFSA-N 0.000 description 4
- VCNYNWHVJKWJRQ-UHFFFAOYSA-N Isorhynchophylline Natural products CCC1=CN2CCC3(C2CC1C(=COC)C(=O)OC)C(=O)Nc4ccccc34 VCNYNWHVJKWJRQ-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical group O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses the preparation method of eucommia bark depressor oral formulations, it is prepared from by compound eucommia bark fluid extract, Ramulus Uncariae Cum Uncis and adjuvant; The present invention is according to the character of medicine each in eucommia bark depressor oral formulations, and this medicine role in side, is optimized the technique of preparation, and compared with prior art, product active constituent content prepared by technique of the present invention is high, and clinical efficacy is good.
Description
Technical field
The present invention relates to a kind of preparation method of eucommia bark depressor oral formulations, belong to the field of medicine technology.
Technical background
Hypertension is the modal cardiovascular disease in the world, is also one of maximum epidemic diseases.Often cause the infringement of brain, the heart, kidney, it causes human death's principal disease as the most important risk factor of coronary heart disease, cerebrovascular disease.According to statistics, there are 1,000,000,000 hyperpietics in the whole world, China's 1.3 hundred million (accounting for 11.36%), annual new patient 300 ~ 4,000,000 example, the U.S. 5,000 ten thousand patient (account for and be greater than 20%).Therefore, control to hypertension and research are all paid much attention in countries in the world.
Modern medicine is thought that hypertensive treatment is not only and is reduced blood pressure, and the more important thing is protection target organ, reduces the incidence rate of cardiovascular diseases, case fatality rate and disability rate.Current antihypertensive drug can be divided into medicine (the mainly α of diuretic, beta-blocker, calcium ion antagonist (CCB), angiotensin-convertion enzyme inhibitor (ACEI), Angiotensin Ⅱ receptor antagonist (ARB) and direct blood vessel dilating
1receptor blocking agent) six classes.But conventional depressor has side effect and serious drug resistance, and even some medicine life-time service has nephrotoxicity.
The traditional Chinese medical science is divided into hyperactivity of liver-fire, type of deficiency of YIN leading to hyper activity of YANG, deficiency of both YIN and YANG type, qi deficiency and phlegm stagnation syndrome type 4 pattern of syndrome hypertension.Primary treatments has the eliminating evil method of dispelling wind, nourishing the liver and kidney suppressing the hyperactive liver to relieve the wind syndrome method, cold expelling spasmolysis, warming YANG to expel cold relieving spasm by calming endogenous wind method, QI invigorating warming YANG to induce diutesis method, endogenous wind stopping Circulation Resolving Phlegm, and the methods such as heat clearing away cool liver endogenous wind stopping method and coordinating YIN and YANG method are treated.Duzhong Jiangya Tablets is again compound eucommia bark sheet, is prepared from by compound eucommia bark fluid extract, Ramulus Uncariae Cum Uncis, and wherein compound eucommia bark fluid extract is prepared from by the Cortex Eucommiae (stir-fry), Herba Leonuri, Spica Prunellae, Radix Scutellariae and Ramulus Uncariae Cum Uncis again.In side, Cortex Eucommiae sweet in the mouth, warm in nature, returns liver, kidney channel, have invigorating the liver and kidney, bone and muscle strengthening, antiabortive effect; For deficiency of the liver and kindey, soreness of waist and knee joint, muscles and bones is unable, has a dizzy spell, blood leaking in gestation, frequent fetal movement.Herba Leonuri bitter in the mouth, pungent, be slightly cold, return liver, pericardium, urinary bladder channel, there is promoting blood flow to regulate menstruation, inducing diuresis to remove edema, effect of heat-clearing and toxic substances removing; For menoxenia, dysmenorrhea amenorrhea, lochiorrhea, edema oliguria, sore swollen toxin.Spica Prunellae acrid in the mouth, hardship, cold in nature, return liver, gallbladder meridian, there is purging liver-fire, improving eyesight, effect of mass dissipating and swelling eliminating; For conjunctival congestion and swelling pain, order pearl nyctalgia, has a headache dizzy, scrofula, goiter, acute mastitis, nodules of the breast, distending pain of the breast.Radix Scutellariae bitter in the mouth, cold in nature, return lung, gallbladder, spleen, large intestine, small intestine meridian, there is heat clearing and damp drying, eliminating fire and detoxication, hemostasis, antiabortive effect; For hygropyrexia, heat-damp in summer, vomiting and nausea uncomfortable in chest, damp and hot feeling of fullness, dysentery, jaundice, cough due to lung-heat, high hot excessive thirst, heat in blood tells nosebleed, carbuncle sore tumefacting virus, frequent fetal movement.Ramulus Uncariae Cum Uncis sweet in the mouth, cool in nature, return liver, pericardium channel, there is dispelling wind and relieving convulsion, effect of heat clearing away suppressing the hyperactive liver; For liver-wind stirring up internally, infantile convulsion is twitched, and hyperpyrexia convulsion, dysphoric cold, children's's night crying due to fright in infant, pre-eclampsia, has a headache dizzy.Modern pharmacological research proves, Duzhong Jiangya Tablets has the kidney invigorating, suppressing the hyperactive liver, the effects such as heat clearing away.Definite curative effect is had for treatment high blood pressure disease.The method of existing production Duzhong Jiangya Tablets is generally adopt (WS3-B-1185-92) upper method recorded, the extracting method that above-mentioned standard is recorded is decocting cooking method, fairly simple, cause containing a large amount of invalid components and impurity in product, make the clinical efficacy of Duzhong Jiangya Tablets not ideal enough.
summary of the invention:
Technical problem to be solved by this invention is the preparation method providing eucommia bark depressor oral formulations.
For solving the problems of the technologies described above, the present invention realizes by the following technical solutions:
A preparation method for eucommia bark depressor oral formulations, calculates according to composition by weight, is prepared from by compound eucommia bark fluid extract by dry cream 150 parts, Ramulus Uncariae Cum Uncis 150 parts; Described eucommia bark depressor oral formulations is prepared like this: Ramulus Uncariae Cum Uncis is ground into fine powder, mixs homogeneously with compound eucommia bark fluid extract, then adds customary adjuvant and conventionally can make different oral formulations, to obtain final product.
In the preparation method of aforementioned eucommia bark depressor oral formulations, described compound eucommia bark fluid extract calculates according to composition by weight, is prepared from by Cortex Eucommiae (parched) 469 parts, Herba Leonuri 469 parts, Spica Prunellae 281 parts, Radix Scutellariae 281 parts, Ramulus Uncariae Cum Uncis 131 parts;
Described compound eucommia bark fluid extract is prepared like this: Cortex Eucommiae (parched), Spica Prunellae, Ramulus Uncariae Cum Uncis are pulverized, and with ethanol ultrasonic extraction 1-3 time of 60%-80%, filtration, filtering residue is for subsequent use; Filtrate leaves standstill 12-48 hour, gets supernatant and reclaims ethanol, be condensed into fluid extract; Filtering residue uses 5-8 times amount soak by water 1-3 time again, each 0.5-2 hour, and filter, merge extractive liquid, is condensed into fluid extract; Separately get Herba Leonuri, Radix Scutellariae water boiling and extraction 1-3 time, add 6-8 times amount soak by water 0.5-2 hour, extracting solution leaves standstill 12-48 hour, gets supernatant concentration and becomes fluid extract at every turn; Above-mentioned fluid extract mixing, to obtain final product.
Specifically, described compound eucommia bark fluid extract is prepared like this: Cortex Eucommiae (parched), Spica Prunellae, Ramulus Uncariae Cum Uncis are ground into 60 object fine powders, the ethanol ultrasonic extraction with 70% 2 times, first time adds 8 times amount 70% ethanol, and second time adds 6 times amount 70% ethanol, each 40 minutes, filter, filtering residue is for subsequent use; Filtrate leave standstill 24 hours, get supernatant reclaim ethanol, be condensed into when relative density is 80 DEG C be 1.35 ~ 1.38 fluid extract; Filtering residue uses 6 times amount soak by water twice again, each 1 hour, filter, merge extractive liquid, be condensed into when relative density is 80 DEG C be 1.35 ~ 1.38 fluid extract; Separately get Herba Leonuri, Radix Scutellariae water boiling and extraction 2 times, first time add 8 times of water gagings, second time add 6 times of water gagings, each 1 hour, extracting solution leave standstill 24 hours, get when supernatant concentration becomes relative density to be 80 DEG C be 1.35 ~ 1.38 fluid extract; Above-mentioned fluid extract mixing, to obtain final product.
In the preparation method of aforementioned eucommia bark depressor oral formulations, described oral formulations refers to tablet or capsule.
Described tablet is prepared like this: hook taking rattan is ground into fine powder, mixs homogeneously with compound eucommia bark fluid extract, and 60 DEG C dry, pulverize, and use 60% alcohol granulation, then adds the magnesium stearate mixing of dry grain amount 1%, and tabletting, sugar coating, obtains tablet.
Described capsule is prepared like this: hook taking rattan is ground into fine powder, mixs homogeneously with compound eucommia bark fluid extract, and 60 DEG C dry, pulverize, and use 60% alcohol granulation, then add the magnesium stearate of the amount of making 0.5%, and mixing, incapsulates, obtain capsule.
In drug prescription of the present invention, the Cortex Eucommiae has invigorating the liver and kidney, bone and muscle strengthening, antiabortive effect, for deficiency of the liver and kindey, soreness of waist and knee joint, muscles and bones is unable, have a dizzy spell, blood leaking in gestation, frequent fetal movement, its principle active component is pinoresinol diglucoside, there is the effect of blood pressure lowering and adjusting blood lipid, also have antitumor, the kidney invigorating, enhancing human body immunity, the pharmacological actions such as Hangzhoupro oxidation, defying age, anti-muscle skeleton are aging, prevent miscarriage; Herba Leonuri has promoting blood flow to regulate menstruation, inducing diuresis to remove edema, effect of heat-clearing and toxic substances removing, and main component is alkaloids, volatile oil, has the pharmacological actions such as regulating menstruation, hemostasis, Ischemic myocardium reperfusion injury, antiplatelet aggregation, reduction blood viscosity; Ramulus Uncariae Cum Uncis has dispelling wind and relieving convulsion, effect of heat clearing away suppressing the hyperactive liver.Its principle active component Ramulus Uncariae cum Uncis alkali and isorhynchophylline, have the multiple action and efficacy such as blood pressure lowering, analgesia, antiinflammatory, antitumor, calmness, antioxidation; Spica Prunellae has purging liver-fire, improving eyesight, effect of mass dissipating and swelling eliminating, its principle active component organic acid, has blood pressure lowering, antibacterial, antiviral and the pharmacological action such as antiinflammatory and antitumor; Radix Scutellariae has heat clearing and damp drying, eliminating fire and detoxication, and hemostasis, antiabortive effect, main component is baicalin, mainly has heat clearing and damp drying, eliminating fire and detoxication, the pharmacological actions such as arresting bleeding and miscarriage prevention.In prior art, compound eucommia bark fluid extract is generally directly use soak by water, but inventor is through experimental studies have found that, Ramulus Uncariae Cum Uncis, the Cortex Eucommiae and Spica Prunellae alcohol extraction effective ingredient extraction rate are higher than water extraction, its fat-soluble effective ingredient of water extraction can not be extracted efficiently out, and extracting method of the present invention makes the effective ingredient of its medicine better extract.
Applicant carried out following experiments, provable the present invention has effective effect;
experimental example 1:compound eucommia bark fluid extract Study on Preparation
Invention formulation technique: Cortex Eucommiae (parched), Spica Prunellae, Ramulus Uncariae Cum Uncis are ground into 60 object fine powders, the ethanol ultrasonic extraction with 70% 2 times, first time adds 8 times amount 70% ethanol, and second time adds 6 times amount 70% ethanol, each 40 minutes, and filter, filtering residue is for subsequent use; Filtrate leave standstill 24 hours, get supernatant reclaim ethanol, be condensed into when relative density is 80 DEG C be 1.35 ~ 1.38 fluid extract; Filtering residue uses 6 times amount soak by water twice again, each 1 hour, filter, merge extractive liquid, be condensed into when relative density is 80 DEG C be 1.35 ~ 1.38 fluid extract; Separately get Herba Leonuri, Radix Scutellariae water boiling and extraction 2 times, first time add 8 times of water gagings, second time add 6 times of water gagings, each 1 hour, extracting solution leave standstill 24 hours, get when supernatant concentration becomes relative density to be 80 DEG C be 1.35 ~ 1.38 fluid extract; Above-mentioned fluid extract mixing, to obtain final product.
Former preparation process: get Cortex Eucommiae (parched), Herba Leonuri, Spica Prunellae, Radix Scutellariae, Ramulus Uncariae Cum Uncis decoct with water three times, each 1 hour, collecting decoction, filter, leave standstill 24 hours, Aspirate supernatant, be concentrated into the fluid extract that relative density is 1.35 ~ 1.38 (80 DEG C), obtain final product.
Detect the content of wherein pinoresinol diglucoside, Ramulus Uncariae cum Uncis alkali, isorhynchophylline, different SHY-2 respectively, the results are shown in Table 1:
Table 1
| Project | Former technique preparation | Invention formulation |
| Pinoresinol diglucoside | 0.31% | 0.38% |
| Ramulus Uncariae cum Uncis alkali | 0.0035% | 0.004% |
| Isorhynchophylline | 0.0021% | 0.0026 |
| Different SHY-2 | 0.085% | 0.11% |
Above experimental result shows, in invention formulation technique extract, the content of pinoresinol diglucoside, Ramulus Uncariae cum Uncis alkali, isorhynchophylline, different SHY-2 is higher, is better than former preparation process.
experimental example 2: pharmacodynamic study
1 sample preparation
Former technique extract: get Cortex Eucommiae (parched) 469g, Herba Leonuri 469g, Spica Prunellae 281g, Radix Scutellariae 281g, Ramulus Uncariae Cum Uncis 131g, decoct with water three times, each 1 hour, collecting decoction, filter, leave standstill 24 hours, Aspirate supernatant, is concentrated into the fluid extract that relative density is 1.35 ~ 1.38 (80 DEG C), obtains compound eucommia bark fluid extract.Hook taking rattan 150g is ground into fine powder, with compound eucommia bark fluid extract (by dry cream juice) 150g, mixs homogeneously, makes the medicinal liquid of 10% concentration (g/ml) by purified water;
Extract of the present invention: get Cortex Eucommiae (parched) 469g, Spica Prunellae 281g, Ramulus Uncariae Cum Uncis 131g is ground into 60 object fine powders, the ethanol ultrasonic extraction with 70% 2 times, first time adds 8 times amount 70% ethanol, second time adds 6 times amount 70% ethanol, each 40 minutes, filter, filtering residue was for subsequent use; Filtrate leave standstill 24 hours, get supernatant reclaim ethanol, be condensed into when relative density is 80 DEG C be 1.35 ~ 1.38 fluid extract; Filtering residue uses 6 times amount soak by water twice again, each 1 hour, filter, merge extractive liquid, be condensed into when relative density is 80 DEG C be 1.35 ~ 1.38 fluid extract; Separately get Herba Leonuri 469g, Radix Scutellariae 281g water boiling and extraction 2 times, first time add 8 times of water gagings, second time add 6 times of water gagings, each 1 hour, extracting solution leave standstill 24 hours, get when supernatant concentration becomes relative density to be 80 DEG C be 1.35 ~ 1.38 fluid extract; Above-mentioned fluid extract mixing, obtains compound eucommia bark fluid extract; Another hook taking rattan 150g is ground into fine powder, and the compound eucommia bark fluid extract made with said method is mixed homogeneously by dry cream 150g, makes the medicinal liquid of 10% concentration (g/ml) by purified water.
2 laboratory animals
Spontaneous hypertensive rat (SHR), artificial lighting 12h/d, by sex sub-cage rearing, 5, every cage, freely drinks water, and feeds with 21% high protein block material, adds block material every day 1 time, change fresh tap water 2 times.By body weight and blood pressure random packet, i.e. A group, (blank group, gives normal saline), B group (former technique preparation, dosage is 0.1g/kg), C group (invention formulation, dosage is 0.1g/kg).
3 experimental techniques
The blood pressure lowering experiment of 3.1 single-doses: SHR male and female dual-purpose, body weight (220 ± 20) g.Before pressure measurement, rat is put into (37 ± 1) DEG C electrothermostat to heat, with CRB-ó type rat computer blood pressure heart rate instrument indirect determination rat tail artery systolic pressure (SBP) after 10min.Before formal experiment, every day pressure measurement training once, about 2 weeks, conforms, after blood pressure stabilization, gets A, B, C, D, E5 group during experiment until rat.To measure before administration and after administration 2,4,12,24h SBP.Adopt t inspection, compare the significance of SBP mean difference before and after animal self administration.
The blood pressure lowering experiment of 3.2 multiple dosings gets A, B, C3 group, daily 1 time.Successive administration 20d, measures SBP (method is the same) every day.T inspection between two groups is adopted to carry out statistical procedures, the significance of more each administration group and matched group SBP mean difference.
4 experimental results
The antihypertensive effect of 4.1 single-doses is observed
After SHR gives pharmaceutical preparation, medicine group all can peaking when 2h, and (3.21 ± 1.20) kpa and (4.03 ± 2.85) kPa, 12h that declines respectively does not return to level before administration yet.
The antihypertensive effect of 4.2 multiple dosings is observed
After giving pharmaceutical preparation continuously, blood pressure slowly declines, and wherein, invention formulation compares with former technique preparation group significant difference, refers to table 2.
The antihypertensive effect that SHR successive administration 20d respectively organized by table 2 compares (x ± s, n=10)
Note: compare with B group, * P < 0.05
Result shows, medicine group all can reduce spontaneous hypertensive rat systolic pressure, and invention formulation is compared than former preparation, better effects if (P < 0.05).
Above experimental studies results shows, invention formulation group and former technique preparation group all can have the effect of blood pressure lowering; Wherein the antihypertensive effect of invention formulation is better than former technique preparation.
Compared with prior art, the present invention is according to the character of medicine each in Duzhong Jiangya Tablets side, and this medicine role in prescription, the technique of eucommia bark depressor oral formulations is optimized, make the refine more of this medicine, drug effect is more remarkable, has better therapeutical effect for treatment high blood pressure disease.Compare with existing preparation, invention formulation active constituent content is high, and statistical analysis shows, and the clinical efficacy of pharmaceutical preparation of the present invention is better, reaches the object of invention.
detailed description of the invention:
Embodiment 1:
Described tablet is prepared like this:
Get Cortex Eucommiae (parched) 469g, Spica Prunellae 281g, Ramulus Uncariae Cum Uncis 131g is ground into 60 object fine powders, the ethanol ultrasonic extraction with 70% 2 times, first time adds 8 times amount 70% ethanol, and second time adds 6 times amount 70% ethanol, each 40 minutes, and filter, filtering residue is for subsequent use; Filtrate leave standstill 24 hours, get supernatant reclaim ethanol, be condensed into when relative density is 80 DEG C be 1.35 ~ 1.38 fluid extract; Filtering residue uses 6 times amount soak by water twice again, each 1 hour, filter, merge extractive liquid, be condensed into when relative density is 80 DEG C be 1.35 ~ 1.38 fluid extract; Separately get Herba Leonuri 469g, Radix Scutellariae 281g water boiling and extraction 2 times, first time add 8 times of water gagings, second time add 6 times of water gagings, each 1 hour, extracting solution leave standstill 24 hours, get when supernatant concentration becomes relative density to be 80 DEG C be 1.35 ~ 1.38 fluid extract; Above-mentioned fluid extract mixing, obtains compound eucommia bark fluid extract;
Another hook taking rattan 150g is ground into fine powder, and the compound eucommia bark fluid extract made with said method is mixed homogeneously by dry cream 150g, and 60 DEG C dry, pulverize, and use 60% alcohol granulation, then adds the magnesium stearate mixing of dry grain amount 1%, and tabletting, sugar coating, obtains tablet.
Usage and consumption: oral, one time 5,3 times on the one.
Embodiment 2:
Described capsule is prepared like this:
Get Cortex Eucommiae (parched) 469g, Spica Prunellae 281g, Ramulus Uncariae Cum Uncis 131g is ground into 60 object fine powders, the ethanol ultrasonic extraction with 70% 2 times, first time adds 8 times amount 70% ethanol, and second time adds 6 times amount 70% ethanol, each 40 minutes, and filter, filtering residue is for subsequent use; Filtrate leave standstill 24 hours, get supernatant reclaim ethanol, be condensed into when relative density is 80 DEG C be 1.35 ~ 1.38 fluid extract; Filtering residue uses 6 times amount soak by water twice again, each 1 hour, filter, merge extractive liquid, be condensed into when relative density is 80 DEG C be 1.35 ~ 1.38 fluid extract; Separately get Herba Leonuri 469g, Radix Scutellariae 281g water boiling and extraction 2 times, first time add 8 times of water gagings, second time add 6 times of water gagings, each 1 hour, extracting solution leave standstill 24 hours, get when supernatant concentration becomes relative density to be 80 DEG C be 1.35 ~ 1.38 fluid extract; Above-mentioned fluid extract mixing, obtains compound eucommia bark fluid extract;
Another hook taking rattan 150g is ground into fine powder, and the compound eucommia bark fluid extract made with said method is mixed homogeneously by dry cream 150g, and 60 DEG C dry, pulverize, and use 60% alcohol granulation, then add the magnesium stearate of the amount of making 0.5%, and mixing, incapsulates, obtain capsule.
Usage and consumption: oral, one time 5,3 times on the one.
Claims (5)
1. a preparation method for eucommia bark depressor oral formulations, is characterized in that: calculate according to composition by weight, described eucommia bark depressor oral formulations is prepared from by dry cream 150 parts, Ramulus Uncariae Cum Uncis 150 parts by compound eucommia bark fluid extract; Described eucommia bark depressor oral formulations is prepared like this: Ramulus Uncariae Cum Uncis is ground into fine powder, mixs homogeneously with compound eucommia bark fluid extract, then adds customary adjuvant and conventionally make different oral formulations, to obtain final product; Described compound eucommia bark fluid extract calculates according to composition by weight, is prepared from by Cortex Eucommiae (parched) 469 parts, Herba Leonuri 469 parts, Spica Prunellae 281 parts, Radix Scutellariae 281 parts, Ramulus Uncariae Cum Uncis 131 parts; Described compound eucommia bark fluid extract is prepared like this: Cortex Eucommiae (parched), Spica Prunellae, Ramulus Uncariae Cum Uncis are pulverized, and with ethanol ultrasonic extraction 1-3 time of 60%-80%, filtration, filtering residue is for subsequent use; Filtrate leaves standstill 12-48 hour, gets supernatant and reclaims ethanol, be condensed into fluid extract; Filtering residue uses 5-8 times amount soak by water 1-3 time again, each 0.5-2 hour, and filter, merge extractive liquid, is condensed into fluid extract; Separately get Herba Leonuri, Radix Scutellariae water boiling and extraction 1-3 time, add 6-8 times amount soak by water 0.5-2 hour, extracting solution leaves standstill 12-48 hour, gets supernatant concentration and becomes fluid extract at every turn; Above-mentioned fluid extract mixing, to obtain final product.
2. the preparation method of eucommia bark depressor oral formulations as claimed in claim 1, it is characterized in that: described compound eucommia bark fluid extract is prepared like this: Cortex Eucommiae (parched), Spica Prunellae, Ramulus Uncariae Cum Uncis are ground into 60 object fine powders, ethanol ultrasonic extraction with 70% 2 times, first time adds 8 times amount 70% ethanol, second time adds 6 times amount 70% ethanol, each 40 minutes, filter, filtering residue was for subsequent use; Filtrate leave standstill 24 hours, get supernatant reclaim ethanol, be condensed into when relative density is 80 DEG C be 1.35 ~ 1.38 fluid extract; Filtering residue uses 6 times amount soak by water twice again, each 1 hour, filter, merge extractive liquid, be condensed into when relative density is 80 DEG C be 1.35 ~ 1.38 fluid extract; Separately get Herba Leonuri, Radix Scutellariae water boiling and extraction 2 times, first time add 8 times of water gagings, second time add 6 times of water gagings, each 1 hour, extracting solution leave standstill 24 hours, get when supernatant concentration becomes relative density to be 80 DEG C be 1.35 ~ 1.38 fluid extract; Above-mentioned fluid extract mixing, to obtain final product.
3. the preparation method of eucommia bark depressor oral formulations according to claim 1, is characterized in that: described oral formulations refers to tablet or capsule.
4. the preparation method of eucommia bark depressor oral formulations according to claim 3, it is characterized in that: described tablet is prepared like this: hook taking rattan is ground into fine powder, mix homogeneously with compound eucommia bark fluid extract, 60 DEG C dry, pulverize, and use 60% alcohol granulation, add the magnesium stearate mixing of dry grain amount 1% again, tabletting, sugar coating, obtains tablet.
5. the preparation method of eucommia bark depressor oral formulations according to claim 3, it is characterized in that: described capsule is prepared like this: hook taking rattan is ground into fine powder, mix homogeneously with compound eucommia bark fluid extract, 60 DEG C dry, pulverize, and use 60% alcohol granulation, add the magnesium stearate of the amount of making 0.5% again, mixing, incapsulates, obtains capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310657766.2A CN103610795B (en) | 2013-12-09 | 2013-12-09 | A kind of preparation method of eucommia bark depressor oral formulations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310657766.2A CN103610795B (en) | 2013-12-09 | 2013-12-09 | A kind of preparation method of eucommia bark depressor oral formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103610795A CN103610795A (en) | 2014-03-05 |
| CN103610795B true CN103610795B (en) | 2016-01-06 |
Family
ID=50161528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310657766.2A Active CN103610795B (en) | 2013-12-09 | 2013-12-09 | A kind of preparation method of eucommia bark depressor oral formulations |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103610795B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107137666A (en) * | 2017-06-08 | 2017-09-08 | 合肥市风达农业有限责任公司 | A kind of effect of Compound Anshen Chinese hypotensor preparation and preparation method thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105876867A (en) * | 2016-04-29 | 2016-08-24 | 张家界久瑞生物科技有限公司 | Eucommia ulmoides extract-containing electronic tobacco liquid and preparation method thereof |
| CN106421020A (en) * | 2016-10-10 | 2017-02-22 | 徐凤芹 | Ligusticum chuanxiong-Gardenia jasminoides oral preparation and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593520A (en) * | 2004-06-18 | 2005-03-16 | 一笑堂（湖南）制药有限公司 | Compound capsule of eucommia bark and its preparing process |
| CN1733116A (en) * | 2005-08-16 | 2006-02-15 | 贵阳德昌祥药业有限公司 | Medicinal preparation for treating hypertension and its preparing process |
| CN1833686A (en) * | 2005-03-15 | 2006-09-20 | 遵义廖元和堂药业有限公司 | Pure Chinese medicinal hypotensor |
| CN101612188A (en) * | 2009-07-01 | 2009-12-30 | 贵州百花医药股份有限公司 | The preparation method and the product of eucommia bark depressor Chinese medicine slow releasing preparation |
| CN101946849A (en) * | 2010-08-31 | 2011-01-19 | 王俊杰 | Depressurization chewing gum and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002255844A (en) * | 2001-02-20 | 2002-09-11 | Kenzen Kyu | Hypotensive preparation |
| JP2010248212A (en) * | 2003-01-31 | 2010-11-04 | Yakult Honsha Co Ltd | Glycation inhibitor and application thereof |
-
2013
- 2013-12-09 CN CN201310657766.2A patent/CN103610795B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593520A (en) * | 2004-06-18 | 2005-03-16 | 一笑堂（湖南）制药有限公司 | Compound capsule of eucommia bark and its preparing process |
| CN1833686A (en) * | 2005-03-15 | 2006-09-20 | 遵义廖元和堂药业有限公司 | Pure Chinese medicinal hypotensor |
| CN1733116A (en) * | 2005-08-16 | 2006-02-15 | 贵阳德昌祥药业有限公司 | Medicinal preparation for treating hypertension and its preparing process |
| CN101612188A (en) * | 2009-07-01 | 2009-12-30 | 贵州百花医药股份有限公司 | The preparation method and the product of eucommia bark depressor Chinese medicine slow releasing preparation |
| CN101946849A (en) * | 2010-08-31 | 2011-01-19 | 王俊杰 | Depressurization chewing gum and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 复方杜仲颗粒制备工艺与质量标准研究;孙世林;《中国优秀博硕士学位论文全文数据库（硕士）工程科技Ⅰ辑》;20040915(第03期);第13-14、32页，尤其第13-14页第3.2.1-3.2.2节，第32页第2.1节 * |
| 夏枯草总黄酮超声提取工艺;阳元娥等;《食品研究与开发》;20110430;第32卷(第4期);第31-34页，尤其摘要，第32页第2.3节 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107137666A (en) * | 2017-06-08 | 2017-09-08 | 合肥市风达农业有限责任公司 | A kind of effect of Compound Anshen Chinese hypotensor preparation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103610795A (en) | 2014-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN104873947A (en) | Medicinal composition for treating dog acute upper gastrointestinal hemorrhage and preparation method thereof | |
| CN103432559B (en) | Traditional Chinese medicine composition for treating spanomenorrhea and dysmenorrhea caused by blood stasis and preparation method and application thereof | |
| CN104825914A (en) | Traditional Chinese medicinal preparation for assisted treatment of breast cancer | |
| CN103610795B (en) | A kind of preparation method of eucommia bark depressor oral formulations | |
| CN105816856A (en) | Traditional Chinese medicine compound for preventing and treating livestock endometritis | |
| CN102716339A (en) | Chinese medicinal composition for treating uremia, and preparation method and application thereof | |
| CN104352793A (en) | Traditional Chinese medicine preparation for treating gastrointestinal bleeding and preparation method thereof | |
| CN101618201B (en) | Medicine for curing vulvar leukoplakia | |
| CN103330837B (en) | Traditional Chinese medicine composition for curing osteoporosis of menopausal women | |
| CN103007145B (en) | Traditional Chinese medicine composition for treating children rotavirus enteritis and preparation method of composition | |
| CN110339276A (en) | Traditional Chinese medicine for treating digestive tract tumor and preparation method thereof | |
| CN103432274B (en) | Medicament for treating migraine and preparation method thereof | |
| CN104887950A (en) | Mastitis treatment traditional Chinese medicine compound | |
| CN104352672A (en) | Tortoise plastron-containing traditional Chinese medicine composition for treating diabetes | |
| CN104840902A (en) | Traditional Chinese medicine preparation for treating ovarian tumor | |
| CN104906551A (en) | Anti-fatigue traditional Chinese medicine, food composition and preparation method | |
| CN104998158A (en) | Pharmaceutical composition for treating liver cirrhosis and application thereof | |
| CN104189289A (en) | Traditional Chinese medicine for treating acute icteric hepatitis and preparation method thereof | |
| CN104013815A (en) | Traditional Chinese medicine for treating recurrent oral ulcer due to deficiency of yin and excess of heat and preparation method of traditional Chinese medicine | |
| CN104826080A (en) | Traditional Chinese medicine preparation for treating angina pectoris | |
| CN104208510A (en) | Medicine for treating chronic nephritis | |
| CN104800646A (en) | Traditional Chinese medicine combination for treating burning month syndrome and preparation method thereof | |
| CN105213975A (en) | A kind of pharmaceutical composition and application thereof for the treatment of liver cirrhosis | |
| CN104645233A (en) | Traditional Chinese medicine preparation for treating hyperplasia of mammary glands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method for preparing eucommia ulmoides step-down oral preparation Effective date of registration: 20160304 Granted publication date: 20160106 Pledgee: Shenzhen HongMian two equity investment partnership (L.P.) Pledgor: BAIHUA MEDICAL GROUP CO.,LTD. Registration number: 2016990000168 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20161208 Granted publication date: 20160106 |
|
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20170608 Granted publication date: 20160106 |
|
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20170608 Granted publication date: 20160106 |
|
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20200608 Granted publication date: 20160106 |
|
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20200608 Granted publication date: 20160106 |
|
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20230608 Granted publication date: 20160106 |
|
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20230608 Granted publication date: 20160106 |